AI/ML Innovations Inc. AIMLF
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AI/ML Innovations Inc. (OTCQB: AIMLF; CSE: AIML) is a Canadian technology company focused on artificial intelligence, machine learning, digital health, and health-tech commercialization. The company operates primarily as a holding and investment platform that acquires, develops, and supports technology businesses using AI-driven analytics, remote monitoring, and predictive healthcare tools. Public disclosures and market filings indicate that its activities are concentrated in digital healthcare applications, data-driven wellness technologies, and software-enabled patient monitoring solutions.
The company’s business model centers on building and commercializing healthcare-related intellectual property through its operating subsidiaries and portfolio investments. Its principal areas of activity have included remote cardiac monitoring, AI-assisted health analytics, wearable-device integration, and digital patient engagement technologies. AI/ML Innovations evolved through acquisitions and strategic investments in healthcare technology businesses, positioning itself as a small-cap AI-focused issuer targeting the intersection of healthcare delivery and machine intelligence. Available public information indicates the company has pursued growth through strategic partnerships and technology commercialization rather than large-scale manufacturing or enterprise software licensing.
Business Operations
AI/ML Innovations generates revenue primarily through its healthcare technology subsidiaries, service agreements, monitoring-related activities, and commercialization of digital health platforms. The company has historically emphasized investments in AI-enabled healthcare monitoring systems and connected health technologies. Public filings identify interests in businesses associated with cardiac health monitoring, patient data analytics, and AI-supported clinical decision tools. The company’s operations are principally based in Canada, though several portfolio activities and customer relationships extend into the United States and other international healthcare markets.
The company controls or maintains interests in multiple operating and investment entities connected to healthcare technology innovation. Publicly referenced subsidiaries and portfolio relationships have included Health Gauge Inc., Tech2Heal SAS, and other health-focused technology initiatives disclosed in corporate filings and investor materials. These businesses have focused on wearable technologies, biometric monitoring, telehealth integration, and AI-assisted diagnostics. Data regarding the scale of revenue contribution by each subsidiary is limited in publicly available disclosures, and some operational details remain inconclusive based on available public sources.
Strategic Position & Investments
AI/ML Innovations has positioned itself as a healthcare AI commercialization company seeking exposure to emerging digital health sectors. Its strategy has emphasized acquiring or investing in early-stage health technology businesses with scalable software or monitoring capabilities. Company disclosures have highlighted interest in preventive healthcare, remote patient monitoring, and machine-learning applications designed to improve clinical efficiency and patient outcomes. The firm has also emphasized intellectual property development and strategic partnerships as part of its growth approach.
Major strategic activity has included investments and ownership stakes in digital health and wearable-health businesses, including Health Gauge Inc. and Tech2Heal SAS. Public filings and investor communications indicate that management has pursued opportunities in AI-driven diagnostics, connected healthcare ecosystems, and biometric analytics. The company has also referenced expansion opportunities related to aging populations, chronic disease monitoring, and decentralized healthcare delivery. While the company has announced various strategic initiatives and collaborations, the long-term commercial scale and financial impact of several projects remain uncertain based on currently available public reporting.
Geographic Footprint
AI/ML Innovations is headquartered in Canada, with operations and investment activities primarily concentrated in the Canadian and U.S. healthcare technology markets. The company trades publicly in both Canada and the United States through the Canadian Securities Exchange and the OTCQB market. Its portfolio companies and strategic relationships have included international elements, particularly in Europe through interests connected to France-based Tech2Heal SAS.
The company’s operational influence remains relatively limited compared with large multinational healthcare technology firms, but its strategic focus has involved international commercialization potential for digital health applications. Public disclosures indicate engagement with customers, technology developers, and healthcare stakeholders across North America and selected international markets. Data regarding the precise scale of international revenues or geographic revenue segmentation is inconclusive based on available public sources.
Leadership & Governance
AI/ML Innovations is led by executives with backgrounds in healthcare technology, finance, capital markets, and corporate development. The company’s governance structure follows standard Canadian public-company practices, with executive leadership overseeing acquisition strategy, investment management, and technology commercialization. Public filings and corporate disclosures emphasize a strategy centered on AI-enabled healthcare innovation, strategic investment selection, and long-term digital health market participation.
Key executives and leadership figures identified in recent public disclosures include:
- Tim Daniels – Chief Executive Officer
- Paul Duffy – Executive Chairman
- Moe Kermani – Director
- George Achilleos – Chief Financial Officer
Leadership communications have consistently emphasized growth through healthcare AI deployment, strategic acquisitions, and expansion of digital monitoring capabilities. Some executive roles and board compositions have changed over time, and investors should consult the most recent public filings for current governance details.